For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback